FEATURED NEWS

• HDA Statement on Drug Affordability Policies

  November 23, 2020

  HDA President and CEO Chester “Chip” Davis, Jr., released the following statement on the announcement by the Department of Health and Human Services (HHS) of an interim final rule to implement a “Most Favored Nation Model” for Medicare Part B and a final rule eliminating the prescription drug rebate system for Medicare Part D.

• HDA Statement on 2020 Presidential Election

  November 8, 2020

  Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released the following statement.

• HDA Research Foundation Survey Depicts Supply Chain's DSCSA Implementation Progress

  November 2, 2020

  A survey released today by the Healthcare Distribution Alliance (HDA) Research Foundation indicates the pharmaceutical supply chain continues to make steady progress to comply with the 2013 Drug Supply Chain Security Act (DSCSA); however, some implementation priorities have shifted amid the initial industry response to the COVID-19 pandemic.

• HDA Statement on Proposed DEA Rule on Suspicious Orders

  November 2, 2020

  Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released the following statement regarding the Drug Enforcement Administration’s (DEA) proposed rule on suspicious orders.

• US Biopharmaceutical Supply Chain Resilient and Effective During Early COVID-19 Response

  October 26, 2020

  A report published by the Healthcare Distribution Alliance (HDA) Research Foundation and Deloitte Consulting LLP found that during the first 90 days of the COVID-19 pandemic, the biopharmaceutical finished goods industry quickly adapted and adjusted to deliver medicines safely and efficiently to patients, with only minimal disruptions.